Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice
The Journal of Cardiovascular Aging · 2022
DOI: 10.20517/jca.2021.30 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Cardiovascular Aging, 2022. Verfasst von Leila Rouhi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, University of Texas Health Sciences Center at Houston…. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, American Heart Association.
Abstract (Originalsprache)
The Cre-LoxP technology, including the tamoxifen (TAM) inducible MerCreMer (MCM), is increasingly used to delineate gene function, understand the disease mechanisms, and test therapeutic interventions. We set to determine the effects of TAM-MCM on cardiac myocyte transcriptome. Expression of the MCM was induced specifically in cardiac myocytes upon injection of TAM to myosin heavy chain 6-MCM (Myh6-Mcm) mice for 5 consecutive days. Cardiac function, myocardial histology, and gene expression (RNA-sequencing) were analyzed 2 weeks after TAM injection. A total of 346 protein coding genes (168 up- and 178 down-regulated) were differentially expressed. Transcript levels of 85 genes, analyzed by a reverse transcription-polymerase chain reaction in independent samples, correlated with changes in the RNA-sequencing data. The differentially expressed genes were modestly enriched for genes involved in the interferon response and the tumor protein 53 (TP53) pathways. The changes in gene expression were relatively small and mostly transient and had no discernible effects on cardiac function, myocardial fibrosis, and apoptosis or induction of double-stranded DNA breaks. Thus, TAM-inducible activation of MCM alters cardiac myocytes gene expression, provoking modest and transient interferon and DNA damage responses without exerting other discernible phenotypic effects. Thus, the effects of TAM-MCM on gene expression should be considered in discerning the bona fide changes that result from the targeting of the gene of interest.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, University of Texas Health Sciences Center at Houston, Houston, TX 77030, USA.
- Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Center for Precision Health, School of Biomedical Informatics and School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- American Heart Association
- Cancer Prevention and Research Institute of Texas
Zitieren
APA
Rouhi, L., Fan, S., Cheedipudi, S. M., Olcum, M., Jeong, H. H., Zhao, Z., Gurha, P., & Marian, A. J. (2022). Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice. The Journal of Cardiovascular Aging. https://doi.org/10.20517/jca.2021.30
Vancouver
Rouhi L, Fan S, Cheedipudi SM, Olcum M, Jeong HH, Zhao Z, et al. Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice. The Journal of Cardiovascular Aging. 2022. doi:10.20517/jca.2021.30
BibTeX
@article{Rouhi2022,
author = {Rouhi, Leila and Fan, Siyang and Cheedipudi, Sirisha M and Olcum, Melis and Jeong, Hyun-Hwan and Zhao, Zhongming and Gurha, Priyatansh and Marian, Ali J},
title = {Effects of tamoxifen inducible MerCreMer on gene expression in cardiac myocytes in mice},
journal = {The Journal of Cardiovascular Aging},
year = {2022},
doi = {10.20517/jca.2021.30}
}
EUVIMED